Amneal Pharmaceuticals, Inc. (AMRX) Net Income (Loss) Attributable to Parent USD 2017 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Amneal Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2017 to 2024.
  • Amneal Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$91.6 M, a 1220% decline year-over-year.
  • Amneal Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$164 M, a 39% increase year-over-year.
  • Amneal Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$79.3 M, a 70.7% increase from 2022.
  • Amneal Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$271 M, a 2156% decline from 2021.
  • Amneal Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was $13.2 M, a 80.6% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$164 M -$91.6 M -$84.7 M -1220% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$79.3 M -$110 M -$98.1 M -815% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 $18.8 M $15.5 M +$23.2 M Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$4.35 M $22.2 M +$264 M Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-08
Q1 2023 -$269 M -$6.94 M +$1.87 M +21.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$271 M -$12 M +$9.77 M +44.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 -$280 M -$7.61 M +$170 K +2.18% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$281 M -$242 M -$272 M -907% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$8.4 M -$8.82 M -$21.6 M -169% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $13.2 M -$21.8 M -$15 M -219% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-14
Q3 2021 $28.1 M -$7.78 M +$13.9 M +64% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $14.3 M $30 M +$54.2 M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$39.9 M $12.7 M -$108 M -89.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 $67.8 M -$6.83 M +$267 M +97.5% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-03
Q3 2020 -$199 M -$21.6 M +$243 M +91.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$443 M -$24.2 M -$7.26 M -43% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$435 M $120 M +$168 M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 -$604 M -$274 M -$265 M -3023% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 -$339 M -$265 M -$272 M -3947% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 -$66.7 M -$16.9 M +$962 K +5.39% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$67.6 M -$47.9 M -$47.9 M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 -$19.7 M -$8.77 M -$8.77 M Oct 1, 2018 Dec 31, 2018 10-K 2021-03-01
Q3 2018 -$11 M $6.89 M +$6.89 M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$17.9 M -$17.9 M -$17.9 M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-05
Q1 2018 $0 $0 Jan 1, 2018 Mar 31, 2018 10-Q 2018-05-15
Q4 2017 $0 Oct 4, 2017 Dec 31, 2017 10-K 2018-03-09
Q3 2017 $0 Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $0 Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.